Abstract 30P
Background
Colorectal cancer (CRC) stands as a formidable contributor to cancer-related mortality globally, motivating ongoing efforts to enhance diagnostic and therapeutic strategies. Among emerging candidates, Suppressor of Cytokine Signalling 6 (SOCS6) has garnered attention for its potential implications in tumorigenesis, including CRC. Previously, dot blot technique revealed that SOCS6 binds to multiple candidates, including the erythropoietin receptor (EPOR), which is known to have role in cancer development. Therefore, SOCS6 could regulate the expression of EPOR to facilitate CRC progression. However, the differential expression patterns of SOCS6 and its correlation with EPOR in CRC is not well elucidated. This study aims to correlate expression levels of SOCS6 with the clinical outcomes using immunohistochemistry and to investigate the functional role of SOCS6 along with its correlation with EPOR in CRC.
Methods
Immunohistochemical staining was performed on a total of 80 formalin-fixed, paraffin-embedded CRC specimens, including 70 cancerous and 10 normal tissues, to unveil SOCS6 expression patterns. Moreover, to investigate the role, SOCS6 was silenced using siRNA and functional assays (cell proliferation, and wound healing) were performed in CRC cell lines (HT-29 and COLO-320DM). Also, qRT-PCR, and western blot were conducted to determine the correlation between SOCS6 and EPOR.
Results
Immunohistochemistry revealed a reduction in SOCS6 expression in CRC specimens compared to the normal tissue, yet not significantly associated with tumour stage or grade. Molecular investigations elucidated significant increase in cell proliferation in SOCS6 silenced HT-29 and COLO-320DM cells, demonstrating its tumor suppressive function. In terms of wound healing assay, the gap closure was significantly higher only in SOCS6 silenced COLO-320DM cells. In addition, silencing SOCS6 resulted in the upregulation of EPOR in COLO-320DM cells, however EPOR levels were reduced in HT-29 cells.
Conclusions
Our current findings suggest the tumour suppressive role of SOCS6 in CRC, with the potential to serve as a diagnostic and therapeutic marker.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Sultan Qaboos University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract